The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•30 March 2026•

1 min read

Merck Reports Positive Phase 3 Results for Oral Cholesterol Drug

Key Facts

1Merck’s experimental drug (enlicitide decanoate) reduced LDL-C levels by 64.6%.

2The drug outperformed existing non-statin therapies like bempedoic acid and ezetimibe in the CORALreef AddOn study.

3These results mark the third successful Phase 3 study for the drug, strengthening its position as an oral alternative to injectable treatments.

Create Free Account

Merck & Co. announced successful results from its Phase 3 CORALreef AddOn study for its experimental oral PCSK9 inhibitor, enlicitide decanoate. The clinical trial demonstrated that the drug reduced bad cholesterol (LDL-C) levels by a significant 64.6%. Notably, the treatment outperformed existing non-statin oral therapies, including bempedoic acid and ezetimibe. This marks the third successful Phase 3 study for the drug, positioning it as a potent oral alternative to current injectable treatments. Analysts view these results as a major milestone for Merck, potentially paving the way for a blockbuster product in the hypercholesterolemia market. The positive data reinforces the company's competitive edge and its progress toward regulatory approval.